A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Sensus Healthcare, Inc.
SRTS
$49M
Mkt Cap
$3.03
+3.06%
Sensus Healthcare, Inc. (SRTS) has a 5-year average return on invested capital (ROIC) of 17.8%. This indicates strong capital allocation and a potential competitive advantage.
Sensus Healthcare, Inc. (SRTS) has a market capitalization of $50M. It is classified as a small-cap stock.
Sensus Healthcare, Inc. (SRTS) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.05%.
Sensus Healthcare, Inc. (SRTS) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Sensus Healthcare, Inc. (SRTS) reported annual revenue of $24 million in its most recent fiscal year, based on SEC EDGAR filings.
Sensus Healthcare, Inc. (SRTS) has a net profit margin of 2.0%. This is a modest margin.
Sensus Healthcare, Inc. (SRTS) generated $-2 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Item 1. BUSINESS Sensus Healthcare, Inc. (together, with its subsidiaries, Sensus Medical Devices Ltd. and Sensus Healthcare Services, LLC, unless the context otherwise indicates, “Sensus,” “we,” “us,” “our,” or the “Company”) is a medical device company committed to providing highly effective, non-invasive, and cost-effective treatments for both oncological and non-oncological skin conditions. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (“SRT”), which is based on over a decade of dedicated research and development, and has successfully incorporated SRT into a portfolio of treatment devices: the SRT-100TM, SRT-100+TM and SRT-100 VisionTM. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in hundreds of thousands of patients around the world. Our business was organized in 2010 and the Company, incorporated in Delaware, completed its initial public offering in 2016.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 36M | 24M | 45M | 27M | 9.6M |
| Net Income | -3.0M | 485K | 24M | 4.1M | -6.8M |
| EPS | $-0.18 | $0.03 | $1.46 | $0.25 | $-0.42 |
| Free Cash Flow | 2.2M | -2.4M | -1.6M | -414K | -793K |
| ROIC | -16.1% | 1.0% | 57.0% | 44.9% | -31.8% |
| Gross Margin | 48.0% | 57.6% | 66.5% | 62.8% | 54.8% |
| Debt/Equity | 0.00 | 0.10 | 0.18 | 0.24 | 0.30 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -5.4M | -382K | 15M | 4.1M | -8.2M |
| Operating Margin | -15.3% | -1.6% | 33.3% | 15.2% | -86.0% |
| ROE | -5.9% | 1.0% | 50.4% | 17.3% | -27.6% |
| Shares Outstanding | 16M | 16M | 17M | 16M | 16M |
| Metric | |||||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 9.6M | 27M | 45M | 24M | 36M |
| Gross Margin | 54.8% | 62.8% | 66.5% | 57.6% | 48.0% |
| R&D | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -8.2M | 4.1M | 15M | -382K | -5.4M |
| Op. Margin | -86.0% | 15.2% | 33.3% | -1.6% | -15.3% |
| Net Income | -6.8M | 4.1M | 24M | 485K | -3.0M |
| Net Margin | -71.4% | 15.2% | 54.4% | 2.0% | -8.4% |
| Non-Recurring | 0 | -1K | 13M | 42K | 42K |
| Returns on Capital | |||||
| ROIC | -31.8% | 44.9% | 57.0% | 1.0% | -16.1% |
| ROE | -27.6% | 17.3% | 50.4% | 1.0% | -5.9% |
| ROA | -21.1% | 13.7% | 42.7% | 0.9% | -5.2% |
| Cash Flow | |||||
| Op. Cash Flow | -434K | -286K | -1.4M | -2.1M | 1.9M |
| Free Cash Flow | -793K | -414K | -1.6M | -2.4M | 2.2M |
| Owner Earnings | -1.5M | -1.3M | -1.9M | -2.7M | 1.3M |
| CapEx | 359K | 128K | 159K | 229K | 259K |
| Maint. CapEx | 722K | 613K | 315K | 275K | 275K |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 |
| D&A | 722K | 613K | 315K | 275K | 275K |
| CapEx/OCF | N/A | N/A | N/A | N/A | 13.6% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 3.0M | 27K | 27K |
| Buyback Yield | N/A | N/A | 2.5% | 0.1% | 0.1% |
| Stock-Based Comp | 386K | 415K | 187K | 328K | 328K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | N/A | N/A | N/A | -24M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | 24M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.30 | 0.24 | 0.18 | 0.10 | 0.00 |
| Interest Coverage | -578.6 | 2060.0 | 39.0 | -0.4 | -0.4 |
| Equity | 21M | 26M | 48M | 49M | 51M |
| Total Assets | 28M | 32M | 57M | 54M | 58M |
| Total Liabilities | 6.5M | 6.2M | 8.7M | 4.9M | 7.1M |
| Intangibles | 676K | 292K | N/A | N/A | N/A |
| Retained Earnings | -22M | -18M | 6.3M | 6.8M | 6.8M |
| Working Capital | 20M | 25M | 46M | 45M | 45M |
| Current Assets | 25M | 31M | 53M | 50M | 50M |
| Current Liabilities | 4.9M | 6.0M | 7.7M | 4.2M | 4.2M |
| Per Share Data | |||||
| EPS | -0.42 | 0.25 | 1.46 | 0.03 | -0.18 |
| Owner EPS | -0.09 | -0.08 | -0.12 | -0.17 | 0.08 |
| Book Value | 1.32 | 1.58 | 2.89 | 3.02 | 3.12 |
| Cash Flow/Share | -0.03 | -0.02 | -0.09 | -0.13 | -0.17 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 16.3M | 16.5M | 16.6M | 16.2M | 16.4M |
| Valuation | |||||
| P/E Ratio | N/A | 25.2 | 5.0 | 80.0 | -16.8 |
| P/FCF | N/A | N/A | N/A | N/A | 23.0 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.3 | 4.0 | 2.5 | 0.8 | 1.0 |
| Price/Sales | 5.2 | 2.6 | 3.6 | 2.7 | 1.4 |
| FCF Yield | -1.1% | -0.4% | -1.3% | -6.1% | 4.4% |
| Market Cap | 71M | 104M | 120M | 39M | 50M |
| Avg. Price | 3.04 | 4.21 | 9.61 | 4.08 | 3.03 |
| Year-End Price | 4.35 | 6.31 | 7.24 | 2.40 | 3.03 |
Sensus Healthcare, Inc. passes 3 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 17.8% with a gross margin of 60.4%. At current prices, the estimated annualized return to fair value is -15.9%.
Sensus Healthcare, Inc. (SRTS) has a debt-to-equity ratio of 0.10. This indicates a conservatively financed balance sheet.
Sensus Healthcare, Inc. (SRTS) reported earnings per share (EPS) of $0.03 in its most recent fiscal year.
Sensus Healthcare, Inc. (SRTS) has a return on equity (ROE) of 1.0%. This indicates moderate shareholder returns.
Sensus Healthcare, Inc. (SRTS) has a 5-year average gross margin of 60.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 4 years of financial data for Sensus Healthcare, Inc. (SRTS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Sensus Healthcare, Inc. (SRTS) has a book value per share of $3.02, based on its most recent annual SEC filing.